Consensus Rating1
Neutral
Highest Price Target1
$49.00
Lowest Price Target1
$4.00
Consensus Price Target1
$14.30

Sage Therapeutics (NASDAQ:SAGE) Stock, Analyst Ratings, Price Targets, Forecasts

Sage Therapeutics Inc has a consensus price target of $14.3 based on the ratings of 22 analysts. The high is $49 issued by Citigroup on May 3, 2023. The low is $4 issued by RBC Capital on November 21, 2024. The 3 most-recent analyst ratings were released by Stifel, TD Cowen, and RBC Capital on December 16, 2024, November 21, 2024, and November 21, 2024, respectively. With an average price target of $6.33 between Stifel, TD Cowen, and RBC Capital, there's an implied 17.94% upside for Sage Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
2
Aug
1
5
2
Oct
1
Nov
0
0
0
0
Dec
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.3
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stifel
TD Cowen
RBC Capital
HC Wainwright & Co.
Scotiabank

1calculated from analyst ratings

Analyst Ratings for Sage Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Sage Therapeutics (SAGE) stock?

A

The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Stifel on December 16, 2024. The analyst firm set a price target for $6.00 expecting SAGE to rise to within 12 months (a possible 11.73% upside). 62 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Sage Therapeutics (SAGE)?

A

The latest analyst rating for Sage Therapeutics (NASDAQ:SAGE) was provided by Stifel, and Sage Therapeutics maintained their hold rating.

Q

When was the last upgrade for Sage Therapeutics (SAGE)?

A

The last upgrade for Sage Therapeutics Inc happened on November 21, 2024 when RBC Capital raised their price target to $4. RBC Capital previously had an underperform for Sage Therapeutics Inc.

Q

When was the last downgrade for Sage Therapeutics (SAGE)?

A

The last downgrade for Sage Therapeutics Inc happened on October 4, 2024 when RBC Capital changed their price target from $10 to $4 for Sage Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Sage Therapeutics (SAGE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sage Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sage Therapeutics was filed on December 16, 2024 so you should expect the next rating to be made available sometime around December 16, 2025.

Q

Is the Analyst Rating Sage Therapeutics (SAGE) correct?

A

While ratings are subjective and will change, the latest Sage Therapeutics (SAGE) rating was a maintained with a price target of $10.00 to $6.00. The current price Sage Therapeutics (SAGE) is trading at is $5.37, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch